Center for Immunology of Emerging Infectious Diseases

人的登革病毒（DENV）感染作为一种新兴的疾病，其重要性稳步增加。 由于缺乏对病毒特异性免疫应答及其在感染性疾病中的作用的了解， 加班。 7“o 保护与疾病为了解决与DENV感染和疾病相关的这些关键问题，我们建立了一个独特的合作联盟，即位于匹兹堡大学的新发传染病免疫学中心（CIEID）。CIEID的重点是使用先前从巴西累西腓患者中获得的独特临床样本，对人类感染DENV病毒的免疫反应进行全面分析，这些样本现已存档在匹兹堡大学疫苗研究中心。我们将使用这些样本来表征抗原呈递细胞在DENV免疫发病机制中的初始作用（项目1），以确定T淋巴细胞与树突状细胞在免疫进展中的相互作用， --. `". 人 <C） 0007 .O- （3p =!! 和疾病（项目2），并定义DENV如何抑制对DENV感染的先天免疫应答（项目3）。这些转化免疫学研究将得到行政和临床核心的支持。预计拟议研究的结果将对DENY特异性免疫在感染和疾病中的作用产生重要的新见解，然后可以为治疗和疫苗开发策略提供信息。还预计CIEID将提供转化免疫学的平台技术和全面专业知识，可随时应用于其他新兴传染病或 3-6 m_3 0-3 ti. （外径） 生物防御病原体

Dengue virus (DENV) infection of humans has steadily increased in importance as an emerging infectious disease, and the development of protective vaccines to DENV disease has been impeded by a lack of understanding of virus-specific immune responses and their role in OT. 7"o protection and disease. To address these critical issues related to DENV infection and disease, we have established a unique collaborative consortium, the Center for Immunology of Emerging Infectious Diseases (CIEID) located at the University of Pittsburgh. The focus of the CIEID is to conduct comprehensive analysis of immune responses to DENV virus infection of humans using the unique clinical samples previously obtained from patients in Recife, Brazil, and now archived at the Center for Vaccine Research at the University of Pittsburgh. We will use these samples to characterize the initial role of antigen-presenting cells in DENV immunopathogenesis (Project 1), to define the interaction of T-Iymphocytes with dendritic cells in the progression of immunity --. `". man <C) 0007 .O- (3p =!! and disease (Project 2), and to define how DENV suppresses innate immune responses to DENV infection (Project 3). These translational immunology studies will be supported by a combined administrative and clinical core. It is anticipated that the results of the proposed studies will produce important new insights into the role of DENy-specific immunity in infection and disease that can then inform strategies for treatment and vaccine development. It is also expected that the CIEID will provide platform technologies and comprehensive expertise in translational immunology that can readily be applied to other emerging infectious diseases or 3-6 m_3 0-3 ti. (OD biodefense pathogens.